FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Wagstaff

Research Profile

Chemicals & Drugs

Disorders

Procedures

Physiology

Complement Activation

Concepts & Ideas

Activities & Behaviors

Drug Evaluation

Co-author Network

Publications

TOP 3
Paul Nathan; John Wagstaff; Emilio Porfiri; Tom Powles; Tim Eisen
UK guidelines for the systemic treatment of renal cell carcinoma.
Shalini Patni; John Wagstaff; Nasima Tofazzal; Myriam Bonduelle; Marsham Moselhi; Euan Kevelighan; Steve Edwards
Metastatic unknown primary tumour presenting in pregnancy: a rarity posing an ethical dilemma.
John Wagstaff
Renal cell cancer: is immunotherapy dead?

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Wagstaff (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Paul Nathan; John Wagstaff; Emilio Porfiri; Tom Powles; Tim Eisen
UK guidelines for the systemic treatment of renal cell carcinoma.
British journal of hospital medicine (London, England : 2005) 2009;70(5):284-6.
2007: Shalini Patni; John Wagstaff; Nasima Tofazzal; Myriam Bonduelle; Marsham Moselhi; Euan Kevelighan; Steve Edwards
Metastatic unknown primary tumour presenting in pregnancy: a rarity posing an ethical dilemma.
Journal of medical ethics 2007;33(8):442-3.
2007: John Wagstaff
Renal cell cancer: is immunotherapy dead?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18 Suppl 9():ix94-7.
2006: Anita E M Dirkx; mirjam oude egbrink; John Wagstaff; Arjan W Griffioen
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis.
Journal of leukocyte biology 2006;80(6):1183-96.
2006: John Wagstaff
New horizons in the treatment of renal cell cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x19-22.
2006: Anita E M Dirkx; mirjam oude egbrink; Karolien Castermans; Daisy W J van der Schaft; Victor L J L Thijssen; Ruud Dings; Lucy Kwee; Kevin H Mayo; John Wagstaff; Jessica C A Bouma-Ter Steege; Arjan W Griffioen
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006;20(6):621-30.
2005: Gordon C Jayson; Clive Mulatero; Malcolm Ranson; Jamal Zweit; Alan Jackson; Lynn Broughton; John Wagstaff; Leif Hakansson; Gerard Groenewegen; J A L Lawrance; Meina Tang; Linda Wauk; Dan Levitt; Sandrine Marreaud; Frederic F Lehmann; Manfred Herold; Heinz Zwierzina
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(4):555-63.
2004: Jessica C A Bouma-Ter Steege; Coen I M Baeten; Victor L J L Thijssen; Sietske Satijn; Inge C L Verhoeven; H F P Hillen; John Wagstaff; Arjan W Griffioen
Angiogenic profile of breast carcinoma determines leukocyte infiltration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(21):7171-8.
2004: G Baaten; Adri C Voogd; John Wagstaff
A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1127-44.
2003: Sjoerd Rodenhuis; Marijke Bontenbal; Louk V A M Beex; John Wagstaff; Dick J Richel; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Harm van Tinteren; Hans L Peterse; Elisabeth M TenVergert; Elisabeth G E de Vries
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
The New England journal of medicine 2003;349(1):7-16.
2003: Anita E M Dirkx; mirjam oude egbrink; Marijke J E Kuijpers; Sandra T van der Niet; Viviane V Th Heijnen; Jessica C A Bouma-Ter Steege; John Wagstaff; Arjan W Griffioen
Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression.
Cancer research 2003;63(9):2322-9.
2002: Daisy W J van der Schaft; Ruud Dings; Quido G de Lussanet; Loes I van Eijk; Annemiek W Nap; Regina G H Beets-Tan; Jessica C A Bouma-Ter Steege; John Wagstaff; Kevin H Mayo; Arjan W Griffioen
The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2002;16(14):1991-3.
2002: Gordon C Jayson; Jamal Zweit; Alan Jackson; Clive Mulatero; Peter Julyan; Malcolm Ranson; Lynn Broughton; John Wagstaff; Leif Hakannson; Gerard Groenewegen; John Bailey; Nigel Smith; David Hastings; J A L Lawrance; Hamied A Haroon; Tim Ward; Alan T McGown; Meina Tang; Dan Levitt; Sandrine Marreaud; Frederic F Lehmann; Manfred Herold; Heinz Zwierzina
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Journal of the National Cancer Institute 2002;94(19):1484-93.
2002: Coen I M Baeten; John Wagstaff; I C L Verhoeven; H F P Hillen; Arjan W Griffioen
Flow cytometric quantification of tumour endothelial cells; an objective alternative for microvessel density assessment.
British journal of cancer 2002;87(3):344-7.
2002: D Huugen; Gerard M J Bos; M Jansen; RI Lalisang; R Jansen; John Wagstaff; Harry C Schouten
Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
The Netherlands journal of medicine 2002;60(4):170-3.
2002: Arnold Baars; A M E Claessen; John Wagstaff; Giuseppe Giaccone; Rik J Scheper; Sybren Meijer; M J A G Schakel; Helen Gall; C J L M Meijer; Jan B Vermorken; HERBERT PINEDO; Alfons J M van den Eertwegh
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma.
British journal of cancer 2002;86(8):1230-4.
2002: Daisy W J van der Schaft; John Wagstaff; Kevin H Mayo; Arjan W Griffioen
The antiangiogenic properties of bactericidal/permeability-increasing protein (BPI).
Annals of medicine 2002;34(1):19-27.
2000: Arnold Baars; A M E Claessen; Alfons J M van den Eertwegh; Helen Gall; Anita G M Stam; Sybren Meijer; Giuseppe Giaccone; Chris J L M Meijer; Rik J Scheper; John Wagstaff; Jan B Vermorken; HERBERT PINEDO
Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(8):965-70.
1999: N P Pappas; H F P Hillen; John Wagstaff; Arjan W Griffioen
[Angiogenesis and the regulation of antitumor defense].
Nederlands tijdschrift voor geneeskunde 1999;143(30):1555-9.
1999: Aafke H Honkoop; Sylvia A Luykx-de Bakker; Klaas Hoekman; S Meyer; O W Meyer; Cees J van Groeningen; Paulus van Diest; Epie Boven; ELSKEN VAN DER WALL; Giuseppe Giaccone; John Wagstaff; HERBERT PINEDO
Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
The oncologist 1999;4(2):106-11.
1999: Sylvia A Luykx-de Bakker; Tanja D de Gruijl; Rik J Scheper; John Wagstaff; HERBERT PINEDO
Dendritic cells: a novel therapeutic modality.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):21-7.
1998: Aafke H Honkoop; John Wagstaff; HERBERT PINEDO
Management of stage III breast cancer.
Oncology 1998;55(3):218-27.
1998: Aafke H Honkoop; Paulus van Diest; JS De Jong; SC Linn; Giuseppe Giaccone; Klaas Hoekman; John Wagstaff; HERBERT PINEDO
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.
British journal of cancer 1998;77(4):621-6.
1997: WM Mulder; Peter L Stern; MJ Stukart; E de Windt; R M Butzelaar; Sybren Meijer; H J Adér; A M E Claessen; Jan B Vermorken; Chris J L M Meijer; John Wagstaff; Rik J Scheper; Elisabeth Bloemena
Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):1923-30.
1997: Aafke H Honkoop; ELSKEN VAN DER WALL; Nicole Feller; Gerrit J Schuurhuis; Wim J F van der Vijgh; Epie Boven; Cees J van Groeningen; Giuseppe Giaccone; Klaas Hoekman; Jan B Vermorken; John Wagstaff; HERBERT PINEDO
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):957-62.
1997: Franca Citarella; A Felici; M Brouwer; John Wagstaff; Antonio Fantoni; C Erik Hack
Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2).
Blood 1997;90(4):1501-7.
1997: Bob W van Oosten; Bernard Uitdehaag; Frederik Barkhof; H P Hartung; John Wagstaff; Chris H Polman
Interleukin-2 therapy does not exacerbate multiple sclerosis.
Neurology 1997;49(2):633-4.
1997: Aafke H Honkoop; HERBERT PINEDO; JS De Jong; Hendrik Verheul; SC Linn; Klaas Hoekman; John Wagstaff; Paulus van Diest
Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer.
American journal of clinical pathology 1997;107(2):211-8.
1997: WM Mulder; Elisabeth Bloemena; MJ Stukart; J Alain Kummer; John Wagstaff; Rik J Scheper
T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.
Gut 1997;40(1):113-9.
1996: Aafke H Honkoop; Klaas Hoekman; John Wagstaff; Cees J van Groeningen; Jan B Vermorken; Epie Boven; HERBERT PINEDO
Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.
British journal of cancer 1996;74(7):1132-6.
1996: W M Mulder; MJ Stukart; E de Windt; John Wagstaff; Rik J Scheper; Elisabeth Bloemena
Mucin-1-related T cell infiltration in colorectal carcinoma.
Cancer immunology, immunotherapy : CII 1996;42(6):351-6.
1996: Aafke H Honkoop; Klaas Hoekman; John Wagstaff; Epie Boven; Cees J van Groeningen; Giuseppe Giaccone; Jan B Vermorken; HERBERT PINEDO
Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):35-9.
1996: A C Ogilvie; C E Hack; John Wagstaff; G J van Mierlo; A J Erenberg; L L Thomsen; K Hoekman; E M Rankin
IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):389-94.
1995: W M Mulder; MJ Stukart; M Roos; R A van Lier; John Wagstaff; Rik J Scheper; Elisabeth Bloemena
Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: removal of tumour cells does not affect tumour-specificity.
Cancer immunology, immunotherapy : CII 1995;41(5):293-301.
1995: Gertjan Wolbink; C Schalkwijk; Joke W Baars; John Wagstaff; H van den Bosch; C Erik Hack
Therapy with interleukin-2 induces the systemic release of phospholipase-A2.
Cancer immunology, immunotherapy : CII 1995;41(5):287-92.
1995: John Wagstaff
The role of biological response modifiers in the management of patients with colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(7-8):1323-5.
1995: M W Dercksen; K Hoekman; JJ Visser; Wim W ten Bokkel Huinink; HERBERT PINEDO; John Wagstaff
Hypotension induced by interleukin-3 in patients on angiotensin-converting enzyme inhibitors.
Lancet 1995;345(8947):448.
1995: John Wagstaff; Joke W Baars; Gertjan Wolbink; K Hoekman; A J Eerenberg-Belmer; C Erik Hack
Renal cell carcinoma and interleukin-2: a review.
European journal of cancer (Oxford, England : 1990) 1995;31A(3):401-8.
1994: Joke W Baars; Gertjan Wolbink; M H Hart; C Erik Hack; A J Eerenberg-Belmer; HERBERT PINEDO; John Wagstaff
The release of interleukin-8 during intravenous bolus treatment with interleukin-2.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(10):929-34.
1994: R Lopez-Lopez; C H Langeveld; P E Pizao; R E van Rijswijk; John Wagstaff; HERBERT PINEDO; Godefridus J Peters
Effect of suramin on adenylate cyclase and protein kinase C.
Anti-cancer drug design 1994;9(4):279-90.
1994: K Hoekman; John Wagstaff; Jan B Vermorken; S Meijer; O W Meijer; HERBERT PINEDO
[Primary high-dose chemotherapy with hematopoietic growth factors followed by surgery and radiotherapy in stage III breast carcinoma; a Phase II study in 15 patients].
Nederlands tijdschrift voor geneeskunde 1994;138(21):1069-73.
1994: W M Mulder; H Koenen; A J van de Muysenberg; Elisabeth Bloemena; John Wagstaff; Rik J Scheper
Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment.
Cancer immunology, immunotherapy : CII 1994;38(4):253-8.
1994: A C Ogilvie; Joke W Baars; A J Eerenberg; C Erik Hack; HERBERT PINEDO; Lambertus G Thijs; John Wagstaff
A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.
British journal of cancer 1994;69(3):596-8.
1994: Klaas Hoekman; Jaap van Doorn; T Gloudemans; O S Hoekstra; J A Maassen; Jan B Vermorken; John Wagstaff; HERBERT PINEDO
Tumour-induced hypoglycaemia: a case report.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):277-81.
1994: R Lopez Lopez; R E van Rijswijk; John Wagstaff; HERBERT PINEDO; Godefridus J Peters
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
European journal of cancer (Oxford, England : 1990) 1994;30A(10):1545-9.
1994: C Erik Hack; A C Ogilvie; B Eisele; PM Jansen; John Wagstaff; Lambertus G Thijs
Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy.
Progress in clinical and biological research 1994;388():335-57.
1993: M W Dercksen; K Hoekman; Wim W ten Bokkel Huinink; E M Rankin; Ria Dubbelman; H van Tinteren; John Wagstaff; HERBERT PINEDO
Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
British journal of cancer 1993;68(5):996-1003.
1993: J W Baars; John Wagstaff; C J Van Groeningen; J B Vermorken; E M Bijvank; HERBERT PINEDO; J J Nauta
Phase II study of interferon-gamma and interleukin-2: tachyphylaxis of toxicity to the liver during increasing immune enhancement.
Journal of the National Cancer Institute 1993;85(5):410-1.
1993: C G Olthof; J W Baars; John Wagstaff; A J M Donker; H Schneider; P M J M de Vries
Determination of capillary leakage due to recombinant interleukin-2 by means of noninvasive conductivity measurements.
European journal of applied physiology and occupational physiology 1993;67(2):168-73.
1993: C Erik Hack; A C Ogilvie; B Eisele; A J Eerenberg; John Wagstaff; Lambertus G Thijs
C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.
Intensive care medicine 1993;19 Suppl 1():S19-28.
1993: R E van Rijswijk; E Cvitkovic; John Wagstaff; C E Myers
Workshop on suramin with emphasis on prostate cancer: re-evaluation of response criteria.
European journal of cancer (Oxford, England : 1990) 1993;29A(3):298-300.
1992: R E van Rijswijk; A C van Loenen; John Wagstaff; E Meijer; R Lopez; Cees J van Groeningen; J J Heimans; HERBERT PINEDO
Suramin: rapid loading and weekly maintenance regimens for cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1788-94.
1992: Joke W Baars; J P de Boer; John Wagstaff; D Roem; A J Eerenberg-Belmer; J Nauta; HERBERT PINEDO; C Erik Hack
Interleukin-2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia.
British journal of haematology 1992;82(2):295-301.
1992: Joke W Baars; J L Coenen; John Wagstaff; Paul Van Der Valk; HERBERT PINEDO
Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.
British journal of cancer 1992;66(4):698-9.
1992: J P de Boer; Gertjan Wolbink; Lambertus G Thijs; Joke W Baars; John Wagstaff; C Erik Hack
Interplay of complement and cytokines in the pathogenesis of septic shock.
Immunopharmacology 1992;24(2):135-48.
1992: R Lopez Lopez; Godefridus J Peters; A C van Loenen; P E Pizao; R E van Rijswijk; John Wagstaff; HERBERT PINEDO
The effect of schedule, protein binding and growth factors on the activity of suramin.
International journal of cancer. Journal international du cancer 1992;51(6):921-6.
1992: Joke W Baars; John Wagstaff; C Erik Hack; Gertjan Wolbink; A J Eerenberg-Belmer; HERBERT PINEDO
Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(3):243-4.
1992: Joke W Baars; C Erik Hack; John Wagstaff; A J Eerenberg-Belmer; Gertjan Wolbink; Lambertus G Thijs; R J M Strack van Schijndel; H L van der Vall; HERBERT PINEDO
The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.
British journal of cancer 1992;65(1):96-101.
1992: J W Baars; J C Fonk; Rik J Scheper; B M von Blomberg-van der Flier; H Bril; P von Valk; HERBERT PINEDO; John Wagstaff
Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study.
Biotherapy (Dordrecht, Netherlands) 1992;4(4):289-97.
1992: Cindy Veenhof; R de Wit; B G Taal; L Y Dirix; John Wagstaff; A Hensen; A C Huldij; P J M Bakker
A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour.
European journal of cancer (Oxford, England : 1990) 1992;28(1):75-8.
1991: K Hoekman; John Wagstaff; Cees J van Groeningen; J B Vermorken; Epie Boven; HERBERT PINEDO
Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.
Journal of the National Cancer Institute 1991;83(21):1546-53.
1991: J W Baars; John Wagstaff; Epie Boven; J B Vermorken; Cees J van Groeningen; Rik J Scheper; J C Fonk; H W Nijman; C R Franks; O Damsma
Phase I study on the sequential administration of recombinant human interferon-gamma and recombinant human interleukin-2 in patients with metastatic solid tumors.
Journal of the National Cancer Institute 1991;83(19):1408-10.
1991: K Hoekman; B M von Blomberg-van der Flier; John Wagstaff; Hemmo Drexhage; HERBERT PINEDO
Reversible thyroid dysfunction during treatment with GM-CSF.
Lancet 1991;338(8766):541-2.
1991: C Erik Hack; John Wagstaff; R J M Strack van Schijndel; A J Eerenberg; HERBERT PINEDO; Lambertus G Thijs; J H Nuijens
Studies on the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock.
Thrombosis and haemostasis 1991;65(5):497-503.
1991: K Hoekman; John Wagstaff; E Boven; C J van Groeningen; J B Vermorken; HERBERT PINEDO
[The hematopoietic growth factor GM-CSF in chemotherapy for advanced breast carcinoma].
Nederlands tijdschrift voor geneeskunde 1991;135(10):415-9.
1991: K Hoekman; John Wagstaff; Gert Ossenkoppele; HERBERT PINEDO
[The application of hematopoietic growth factors in oncology].
Nederlands tijdschrift voor geneeskunde 1991;135(10):409-14.
1991: Jan J Heimans; John Wagstaff; W O Schreuder; JG Wolbers; J W Baars; C H Polman; J G Scharenberg; Rik J Scheper; P A Palmer; C R Franks
Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2.
Surgical neurology 1991;35(3):244-7.
1991: John Wagstaff
Lymphokines and cytokines.
Cancer chemotherapy and biological response modifiers 1991;12():165-92.
1990: Lambertus G Thijs; C Erik Hack; R J M Strack van Schijndel; J H Nuijens; Gertjan Wolbink; A J Eerenberg-Belmer; H Van der Vall; John Wagstaff
Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.
Journal of immunology (Baltimore, Md. : 1950) 1990;144(6):2419-24.
1990: J J van der Hoeven; John Wagstaff
Endocrine tumors.
Cancer chemotherapy and biological response modifiers 1990;11():476-83.
1990: John Wagstaff
Lymphokines and cytokines.
Cancer chemotherapy and biological response modifiers 1990;11():204-34.
1989: A K Ghosh; T Cerny; John Wagstaff; N Thatcher; M Moore
Effect of in vivo administration of interferon gamma on expression of MHC products and tumour associated antigens in patients with metastatic melanoma.
European journal of cancer & clinical oncology 1989;25(11):1637-43.
1989: Lambertus G Thijs; C Erik Hack; R J M Strack van Schijndel; J H Nuijens; Gertjan Wolbink; A J Eerenberg-Belmer; H van der Vall; John Wagstaff
Complement activation and high-dose of interleukin-2.
Lancet 1989;2(8659):395.
1989: J T Plukker; E M Blomjous; John Wagstaff; Sybren Meijer
Primary leiomyosarcoma of the rectum: report of two cases and review of the literature.
The Netherlands journal of surgery 1989;41(4):88-91.
1989: John Wagstaff; Jan B Vermorken; G Schwartsmann; R J Scheper; C Erik Hack; J H Nuijens; A J Eerenberg-Belmer; HERBERT PINEDO
A progress report of a phase I study of interferon-gamma and interleukin-2 and some comments on the mechanism of the toxicity due to interleukin-2.
Cancer treatment reviews 1989;16 Suppl A():105-9.
1989: R J M Strack van Schijndel; H J Voerman; R P Golding; John Wagstaff
Interleukin-2 therapy and blockage of double-lumen catheters.
Lancet 1989;1(8644):962-3.
1989: Richard A Cowan; M Jones; M Harris; W P Steward; John A Radford; John Wagstaff; David P Deakin; Derek Crowther
Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
British journal of cancer 1989;59(2):276-82.
1988: Anthony Howell; J Mackintosh; M Jones; J Redford; John Wagstaff; R A Sellwood
The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast.
European journal of cancer & clinical oncology 1988;24(10):1567-72.
1988: John Wagstaff; Walter Gregory; R Swindell; D Crowther; T A Lister
Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres.
British journal of cancer 1988;58(4):487-92.
1988: D Hamilton; Richard A Cowan; M Drayson; H Sharma; P E Cummins; P M Nuttall; David P Deakin; John Wagstaff; Derek Crowther
114Inm oxine-labelled lymphocytes--therapeutic applications.
Nuclear medicine communications 1988;9(10):797-802.
1988: Heather Anderson; John Wagstaff; Derek Crowther; Ric Swindell; Michael Lind; J McGregor; M S Timms; D Brown; P Palmer
Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
European journal of cancer & clinical oncology 1988;24(9):1471-9.
1988: S H Goey; John Wagstaff; HERBERT PINEDO
Biological approaches to the treatment of cancer.
The Netherlands journal of medicine 1988;33(1-2):41-7.
1988: D Hamilton; Richard A Cowan; Harbans L Sharma; M Drayson; P M Nuttall; John Wagstaff; David P Deakin; Derek Crowther
The behavior of autologous indium-114m-labeled lymphocytes in patients with lymphoid cell malignancy.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1988;29(4):485-93.
1988: S H Goey; H J Voerman; R J M Strack van Schijndel; J J van der Hoeven; John Wagstaff; L G Thijs; HERBERT PINEDO
Swelling of metastatic tumors with high-dose interleukin therapy.
The New England journal of medicine 1988;318(10):643-4.
1988: W P Steward; Derek Crowther; L J McWilliam; J M Jones; David P Deakin; I D Todd; G Blackledge; John Wagstaff; John Howard Scarffe; M Harris
Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors.
Cancer 1988;61(3):441-7.
1988: John Wagstaff; K Melief
Lymphokines and cytokines.
Cancer chemotherapy and biological response modifiers 1988;10():416-33.
1987: D B Smith; John Howard Scarffe; John Wagstaff; R J Johnston
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports 1987;71(12):1265-6.
1987: D B Smith; B W Fox; N Thatcher; W P Steward; John Howard Scarffe; John Wagstaff; R Vezin; D Crowther
Phase I clinical trial of methylene dimethane sulfonate.
Cancer treatment reports 1987;71(9):817-20.
1987: D B Smith; Anthony Howell; John Wagstaff
Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival.
European journal of cancer & clinical oncology 1987;23(7):979-82.
1987: D Crowther; John Wagstaff
Management of high-grade non-Hodgkin's lymphoma in adults.
Baillière's clinical haematology 1987;1(1):157-83.
1987: D Smith; John Wagstaff; Nick Thatcher; H Scarffe
A phase I study of rDNA alpha-2b interferon as a 6-week continuous intravenous infusion.
Cancer chemotherapy and pharmacology 1987;20(4):327-31.
1987: John Howard Scarffe; John Wagstaff; D Crowther
Clinical use of interferon alfa-2b (intron-A): the Manchester experience.
Annali dell'Istituto superiore di sanità 1987;23(4):777-8.
1987: John Wagstaff; I Todd; David P Deakin; P Wilkinson; John Howard Scarffe; M Harris; M Jones; D Crowther
A randomized trial of two types of adjuvant chemotherapy in radiotherapy-treated patients with clinical stages I and II high-grade non-Hodgkin's lymphoma.
Cancer chemotherapy and pharmacology 1987;20(1):53-8.
1987: John Wagstaff; D Smith; P Nelmes; P Loynds; D Crowther
A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.
Cancer immunology, immunotherapy : CII 1987;25(1):54-8.